As the healthcare system moves more towards a value-based system, practices are running into challenges with the operational complexities of new payment models. Brenton Fargnoli, MD, medical director of value-based care and director of product marketing and strategy at Flatiron Health, outlined a few ways practices can ensure they’re ready to take on downside risk.
As the healthcare system moves more towards a value-based system, practices are running into challenges with the operational complexities of new payment models. Brenton Fargnoli, MD, medical director of value-based care and director of product marketing and strategy at Flatiron Health, outlined a few ways practices can ensure they’re ready to take on downside risk.
Transcript
What is one of the most common challenges you see practices running into during the transition to value-based care?
The operational complexities of these value-based care requirements is a really common challenge among practices. Particularly, the administrative needs: patient identification, patient tracking, care plan documentation and completion, quality measure calculation and reporting. All of these things add a lot of time and hours to practices’ already busy days. We’ve seen that this is a particularly acute challenge for independent practices, as well as those operating in multiple value-based care programs.
How can practices make sure that they are ready to take on downside risk if it becomes a mandate instead of an option?
So with OCM [Oncology Care Model] and MIPS [Merit-based Incentive Payment System] we’ve seen downside risk is really rapidly moving from an option to a mandate. And there’s a few things practices can do to start preparing for this.
One is really distributing and limiting the risk they’re taking. So, they can do this through practice growth, IPA [independent practice association] affiliation, or even reinsurance. Another is really starting to measure value with clinical granularity. That means taking cost data and really marrying that up with clinical data. And a third piece is just leveraging technology to facilitate this transition to value-based care.
All that being said, I think most importantly, practices need to prove success, frankly, to themselves with the risk adjustment methodology of these upside models, before they’re going to be ready and willing to take the next step to downside risk.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More